Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
Priya S. Kishnani(Duke Medical Center), Yin‐Hsiu Chien(National Taiwan University Hospital), Shugo Suwazono(United States Naval Hospital Okinawa), Kathryn M. Wilson(Monash Health), Magali Periquet(Sanofi (Germany)), Andreas Hahn, Alexander Broomfield(St Mary's Hospital), Julie L. Batista(Sanofi (United States)), Nadia Daba, Zuhair N. Al‐Hassnan(King Faisal Specialist Hospital & Research Centre), David Kronn(New York Medical College), Juan Clinton Llerena(Fundação Oswaldo Cruz)
Cited by 16
Related Papers
Biparental Inheritance of Mitochondrial DNA in Humans
|Proceedings of the National Academy of Sciences|2018|451
Glycogen Storage Disease Type III diagnosis and management guidelines
|Genetics in Medicine|2010|305
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
|Genetics in Medicine|2009|292
Schwannomatosis
|Neurology|1996|244
Targeted long-read sequencing identifies missing disease-causing variation
|The American Journal of Human Genetics|2021|239